COVID-19 Pandemic Lockdowns' Impact on Visual Acuity of Diabetic Macular Edema: A Large Cohort.

IF 2.1 4区医学 Q2 OPHTHALMOLOGY

Ophthalmologica Pub Date : 2023-01-01 DOI:10.1159/000527942

Nir Gomel, Reut Shor, Naama Lippin, Ori Segal, Eran Greenbaum, Shulamit Schwartz, Omer Trivizki, Anat Loewenstein, Gilad Rabina

{"title":"COVID-19 Pandemic Lockdowns' Impact on Visual Acuity of Diabetic Macular Edema: A Large Cohort.","authors":"Nir Gomel, Reut Shor, Naama Lippin, Ori Segal, Eran Greenbaum, Shulamit Schwartz, Omer Trivizki, Anat Loewenstein, Gilad Rabina","doi":"10.1159/000527942","DOIUrl":null,"url":null,"abstract":"Introduction: The objective of this study was to evaluate the impact of unplanned treatment gap, secondary to COVID-19 pandemic lockdowns, on visual acuity in previously treated diabetic macular edema (DME) patients.Methods: A multicenter, retrospective study of DME patients, previously treated with anti-VEGF injections, who were followed up during COVID-19 pandemic (2020) compared to pre-CO-VID-19 period (2019).Results: A total of 634 DME patients with a mean age of 68.4 years met the inclusion criteria, 385 were assessed in 2019 (pre-COVID-19) and 239 patients assessed in 2020 (COVID-19). Baseline best corrected visual acuity (BCVA) among patients in 2019 and 2020 was 0.52 ± 0.44, 0.45 ± 0.43 (logarithm of the minimal angle of resolution, respectively). There was no significant difference between the years 2020 and 2019 in baseline BCVA (p = 0.07). Mean number of anti-VEGF injections was significantly lower (5 vs. 6, p < 0.01), with a major lower ratio of injections per patient in the COVID-19 first lockdown period (March-June 2020) in the COVID-19 group. Baseline BCVA (p < 0.01) was the only significant predictor of final BCVA. Number of injections, age, gender, and the year were not found as predictors of final BCVA.Conclusions: In a large cohort of DME patients, an unplanned delay in treatment with anti-VEGF injections for 2-3 months, due to COVID-19 pandemic lockdown, had no significance impact on visual acuity. For most patients, returning to routine treatment regimen was sufficient for maintaining BCVA.","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000527942","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Introduction: The objective of this study was to evaluate the impact of unplanned treatment gap, secondary to COVID-19 pandemic lockdowns, on visual acuity in previously treated diabetic macular edema (DME) patients.

Methods: A multicenter, retrospective study of DME patients, previously treated with anti-VEGF injections, who were followed up during COVID-19 pandemic (2020) compared to pre-CO-VID-19 period (2019).

Results: A total of 634 DME patients with a mean age of 68.4 years met the inclusion criteria, 385 were assessed in 2019 (pre-COVID-19) and 239 patients assessed in 2020 (COVID-19). Baseline best corrected visual acuity (BCVA) among patients in 2019 and 2020 was 0.52 ± 0.44, 0.45 ± 0.43 (logarithm of the minimal angle of resolution, respectively). There was no significant difference between the years 2020 and 2019 in baseline BCVA (p = 0.07). Mean number of anti-VEGF injections was significantly lower (5 vs. 6, p < 0.01), with a major lower ratio of injections per patient in the COVID-19 first lockdown period (March-June 2020) in the COVID-19 group. Baseline BCVA (p < 0.01) was the only significant predictor of final BCVA. Number of injections, age, gender, and the year were not found as predictors of final BCVA.

Conclusions: In a large cohort of DME patients, an unplanned delay in treatment with anti-VEGF injections for 2-3 months, due to COVID-19 pandemic lockdown, had no significance impact on visual acuity. For most patients, returning to routine treatment regimen was sufficient for maintaining BCVA.

查看原文本刊更多论文

COVID-19大流行封锁对糖尿病黄斑水肿患者视力的影响:一项大队列研究

本研究的目的是评估继发于COVID-19大流行封锁的计划外治疗间隙对先前治疗过的糖尿病黄斑水肿(DME)患者视力的影响。方法:对先前接受过抗vegf注射治疗的DME患者进行多中心回顾性研究，并在2019年COVID-19大流行期间(2020年)与COVID-19前期(2019年)进行随访。结果:符合纳入标准的DME患者共634例，平均年龄68.4岁，2019年评估385例(COVID-19前期)，2020年评估239例(COVID-19)。2019年和2020年患者基线最佳矫正视力(BCVA)分别为0.52±0.44、0.45±0.43(最小分辨角的对数)。2020年和2019年基线BCVA无显著差异(p = 0.07)。抗vegf注射的平均次数显著低于对照组(5次vs. 6次，p < 0.01)，在COVID-19第一次封锁期间(2020年3月至6月)，每名患者的注射比例显著低于对照组。基线BCVA (p < 0.01)是最终BCVA的唯一显著预测因子。注射次数、年龄、性别和年份不能作为最终BCVA的预测因子。结论:在一项大型DME患者队列中，由于COVID-19大流行封锁而非计划延迟抗vegf注射治疗2-3个月，对视力没有显著影响。对于大多数患者，恢复常规治疗方案足以维持BCVA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmologica 医学-眼科学

CiteScore

5.10

自引率

3.80%

发文量

审稿时长

3 months

期刊介绍： Published since 1899, ''Ophthalmologica'' has become a frequently cited guide to international work in clinical and experimental ophthalmology. It contains a selection of patient-oriented contributions covering the etiology of eye diseases, diagnostic techniques, and advances in medical and surgical treatment. Straightforward, factual reporting provides both interesting and useful reading. In addition to original papers, ''Ophthalmologica'' features regularly timely reviews in an effort to keep the reader well informed and updated. The large international circulation of this journal reflects its importance.